Various studies have shown that the expression of PRKCB is significantly increased in a variety of tumour cells such as lung cancer, nasopharyngeal carcinoma, human non-small cell carcinoma, and other malignant tumour cells. Here, PRKCB is linked to non-small cell lung carcinoma.